{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:06:07Z","timestamp":1784066767727,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e35142","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:43:49Z","timestamp":1721868229000},"page":"e35142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Visual improvement in a case of neuromyelitis optica spectrum disorder-related optic neuritis after 18 months of treatment with satralizumab: A case report"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0276-0904","authenticated-orcid":false,"given":"Yao","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-4711","authenticated-orcid":false,"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e35142_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.heliyon.2024.e35142_bib2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.heliyon.2024.e35142_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.heliyon.2024.e35142_bib4","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib5","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.heliyon.2024.e35142_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","volume":"271","author":"K\u00fcmpfel","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib7","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1177\/1352458516687403","article-title":"Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders","volume":"23","author":"Kim","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.heliyon.2024.e35142_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103258","article-title":"Neuromyelitis optica spectrum disorders: a nationwide Portuguese clinical epidemiological study","volume":"56","author":"Santos","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.heliyon.2024.e35142_bib9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e35142_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200071","article-title":"Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar","volume":"10","author":"Kleiter","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.heliyon.2024.e35142_bib11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.604445","article-title":"Different targets of monoclonal antibodies in neuromyelitis optica spectrum disorders: a meta-analysis evidenced from randomized controlled trials","volume":"11","author":"Xue","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.heliyon.2024.e35142_bib14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12883-021-02488-y","article-title":"Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis","volume":"21","author":"Kharel","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4951491","article-title":"A longitudinal comparison of the recovery patterns of optic neuritis with MOG antibody-seropositive and AQP4 antibody-seropositive or -seronegative for both antibodies","volume":"2022","author":"Zhou","year":"2022","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib16","article-title":"Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2017.04.001","article-title":"Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients","volume":"307","author":"Barros","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.heliyon.2024.e35142_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200141","article-title":"Modeling MOG antibody-associated disorder and neuromyelitis optica spectrum disorder in animal models: visual system manifestations","volume":"10","author":"Remlinger","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024111735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024111735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:51:01Z","timestamp":1784065861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024111735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024111735"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35142","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual improvement in a case of neuromyelitis optica spectrum disorder-related optic neuritis after 18 months of treatment with satralizumab: A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e35142"}}